Patent ID: 8445433

Claim:
A solid phase conjugated GLP-1 or GLP-1 agonist peptide, wherein said peptide is of formula SEQ ID NO: 1 A-(R1)x-(R2)y-R3-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser- Ser-Tyr-Leu-Glu-R8-Gln-Ala-Ala-Lys-Glu-Phe-Ile- Ala-Trp-Leu-Val-R4-R5-(R6)w-(R7)z-S or is of formula SEQ ID NO: 3 A-(R1)x-(R2)y-R3-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser- Ser-S or is of formula SEQ ID NO: 4 A-(R1)x-(R2)y-R3-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser- Ser-Tyr-Leu-Glu-Gly-S or is of formula SEQ ID NO: 5 A-(R1)x-(R2)y-R3-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser- Ser-Tyr-Leu-Glu-R8-Gln-Ala-Ala-Lys-Glu-Phe-Ile- Ala-Trp-Leu-Val-R4-S or is of formula SEQ ID NO: 6 A-(R1)x-(R2)y-R3-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser- Ser-Tyr-Leu-Glu-R8-Gln-Ala-Ala-Lys-Glu-Phe-Ile- Ala-Trp-Leu-Val-R4-Gly-S wherein S=solid phase bonded C-terminally covalently to the peptidyl moiety via thioester, ester or amido group or optionally covalently via, where the C-terminal amino acid is a lysine, the ε-amino function of said lysine; A=H-, Ac-, Boc-, Fmoc-; R1=His, D-His, desamino-histidine, 2-amino-histidine, β-hydroxy-histidine, homohistidine, alpha-fluoromethyl-histidine or alpha-methyl-histidine; R2=Ala, D-Ala, Val, D-Val, Gly, Aib (α-aminoisobutyric acid); R3=Glu, Asp, Met, Leu; R4=-Lys or Arg; R5=-Gly, Aib, Ala, D-Ala; R6=Arg, Lys or Gly; R7=Arg, Lys or Gly; R8=Gly or Aib; and wherein, independently, x, y, w, z are 0 or 1, with the proviso that y=1 where x=1 and with the proviso that w=1 where z=1, wherein individual side chains of at least Lys, Thr, Ser, Glu, Asp carry non-base labile protection groups which protection groups may be pseudoproline protection groups which form pseudoproline protected residues in case of Thr or Ser and wherein a first pseudoproline protected residue is located in the unique sequence segment -Val-Ser-Ser and is a pseudoproline-oxazolidine derivative of Serine.